Sept. 14, 2016—Horizon Discovery Group has entered into a co-development and commercialization agreement with Ventana Medical Systems, a member of the Roche Group. The agreement covers the development, manufacture, and commercialization of cell-line derivative materials for use as IHC reference standards in cancer tissue diagnostics to support the development and validation of IHC assays.
Ventana provides products used in clinical histology and drug development research laboratories worldwide. To support the development and validation of IHC assays, Ventana has partnered with Horizon as a leading provider of highly characterized reference standards.
Under the terms of the agreement, Ventana has the option to commission projects from Horizon, whereupon Horizon will develop the applicable cell lines and the associated derivative reference standard materials. Horizon will retain primary responsibility for commercializing the reference standards and will serve as the primary distribution channel to end-customers in the growing tissue diagnostics market. Ventana will hold the option to co-distribute any developed reference standards.
“By securing this agreement, Horizon’s reference standards will now be used increasingly in the IHC market, continuing the company’s successful strategy of embedding OTS products into established and emerging workflows, delivering reliable revenue streams at high margin,” Horizon CEO Darrin Disley, PhD, said in a statement.